V gamma 9V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs - Rituximab and trastuzumab

V gamma 9V delta 2 T cells exert potent cytotoxicity toward various tumor cells and adoptive transfer of V gamma 9V delta 2 T cells is an attractive proposition for cell based immunotherapy. V gamma 9V delta 2 T cells expanded in the presence of Zoledronate and IL-2 express CD16 (Fc gamma RIII), which raises the possibility that V gamma 9V delta 2 T cells could be used in conjunction with tumor targeting monoclonal antibody drugs to increase antitumor cytotoxicity by antibody dependent cellular cytotoxicity (ADCC). Cytotoxic activity against CD20-positive B lineage lymphoma or chronic lymphocytic leukemia (CLL) and HER2-positive breast cancer cells was assessed in the presence of rituximab and trastuzumab, respectively. Cytotoxicity Of V gamma 9V delta 2 T cells against CD20-positive targets was higher when used in combination with rituximab. Similarly, V gamma 9V delta 2 T cells used in combination with trastuzumab resulted in greater cytotoxicity against HER2-positive cells in comparison with either agent alone and this effect was restricted to the CD16(+)V gamma 9V delta 2 T cell population. Our results show that CD16(+)V gamma 9V delta 2 T cells recognize monoclonal antibody coated tumor cells via CD16 and exert ADCC similar to that observed with NK cells, even when target cells are relatively resistant to monoclonal antibodies or V gamma 9V delta 2 T cells alone. Combination therapy involving ex vivo expanded CD16(+)V gamma 9V delta 2 T cells and monoclonal antibodies may enhance the clinical outcomes for patients treated with monoclonal antibody therapy. (C) 2008 Wiley-Liss, Inc.